In an interconnected global economy, geopolitical events can send ripples across markets, affecting investment strategies and outcomes. From the Ukraine-Russia conflict to sudden escalations in Israel, investors find themselves navigating an ever-evolving landscape. This article covers recent events, with a spotlight on Israel-based businesses. [more]
The size of the market for treatable mental health disorders is currently $300 billion in the U.S. and is expected to grow over the next five years. An opportunity exists for clinical-stage companies to commercialize their operations with alternative treatment methods to fill this need. The following article describes the commercialization developments, market capitalizations, and price performances of 6 companies in the industry. [more]
In this short video, Tracy Weslosky of InvestorIntel interviews Chris Thompson of eResearch about eResearch’s Update Report on Xortx Therapeutics pertaining to the Company’s recent $21 million financing and U.S. listing. [more]
New 25-page Update Equity Research Report on XORTX, with a Buy rating and one-year price target of $26.00/share. The Company has two potential late-stage drugs in development focused on kidney diseases with one drug that could be approved within the next 18 months and the other drug that could have an orphan drug indication on the market in 2025. [more]
eResearch published a 27-page Valuation Research Report on StageZero using three valuation methodologies: (1) Comparative Company Analysis using Revenue, (2) Prior Mergers and Acquisitions Analysis, and (3) Discounted Cash Flow. Using the three methodologies and various revenue & growth assumptions, the results estimated the stock price between $0.67 and $14.14. [more]
Patients hospitalized by COVID-19 that end up in intensive care are likely to be diagnosed with acute kidney injury (AKI), face few treatment options and a high mortality rate, but a new potential option is on the way. [more]
In a few short months, ScreenPro Security has emerged as a one-stop shop for Canadian COVID-19 testing and international travelers needing digital COVID-19 passport capabilities. [more]
Investors inject cash into Eupraxia Pharmaceuticals during its IPO on the TSX. The funds will be used to support clinical trials of their leading knee osteoarthritis treatment. Eupraxia’s polymer technology promises to flatten the drug-dose curve, providing long-term pain relief (up to 6 months) with fewer side effects. [more]
After its public listing last October, shares in Canbud appear poised to move higher as it executes on its three-pronged business model: 1) Hemp for cannabinoids (CBD) production, (2) Mushrooms for both psychedelic pharmaceuticals and non-psychedelic nutraceuticals, and (3) Plant-based products. [more]
Graphene-based products manufacturer sees increased demand driven by COVID-19 pandemic and reported its strongest quarter to date with revenue of US$1.2 million, a 497% increase. [more]
Copyright © 2024 | MH Magazine WordPress Theme by MH Themes